Journal List > J Korean Orthop Assoc > v.52(5) > 1013550

Cho, Jeon, Kong, Lee, and Song: Locking Mechanism Failure after Distal Femoral Reconstruction with Modular Universal Tumor and Revision System (MUTARS) Tumor Prosthesis

Abstract

Purpose

We have used Modular Universal Tumor and Revision System (MUTARS) tumor prosthesis to reconstruct segmental resection defect of the distal femur. The purpose of this study was to evaluate the incidence and pattern of locking mechanism breakage and its correlation with other clinical variables.

Materials and Methods

We retrospectively reviewed 94 patients who were followed-up for more than one year after tumor prosthesis replacement (MUTARS) between 2008 and 2013. We examined the incidence and timing of locking mechanism (PEEK-OPTIMA) failure. We also evaluated the clinical characteristics of patients experiencing locking mechanism failure and compared them with those of other patients.

Results

At a mean follow-up of 55 months, we observed locking mechanism failure in 10 of 94 patients (10.6%). The mean age of patients with locking mechanism failure was 29 years (range, 13-54 years); the mean weight and height were 169 cm (range, 151-181 cm) and 67 kg (range, 53-89 kg), respectively. The mean body mass index was 23.5 kg/m2 (range, 20.5-29.4 kg/m2). The median time interval between replacement and locking mechanism failure was 26.5 months (range, 12-72 months). The mean body weight of patients with failure was higher than that of patients without failure (p=0.019).

Conclusion

The incidence of locking mechanism (PEEK-OPTIMA) failure after distal femoral reconstruction with MUTARS was 11%, and there was a correlation between failure and body weight of patients. Advancements in the design and material of locking mechanisms are warranted to reduce the complication.

REFERENCES

1. Myers GJ, Abudu AT, Carter SR, Tillman RM, Grimer RJ. Endoprosthetic replacement of the distal femur for bone tumours: long-term results. J Bone Joint Surg Br. 2007; 89:521–6.
2. Chandrasekar CR, Grimer RJ, Carter SR, Tillman RM, Abu-du A, Buckley L. Modular endoprosthetic replacement for tumours of the proximal femur. J Bone Joint Surg Br. 2009; 91:108–12.
crossref
3. Pala E, Trovarelli G, Calabrò T, Angelini A, Abati CN, Rug-gieri P. Survival of modern knee tumor megaprostheses: failures, functional results, and a comparative statistical analysis. Clin Orthop Relat Res. 2015; 473:891–9.
crossref
4. Jeys LM, Kulkarni A, Grimer RJ, Carter SR, Tillman RM, Abudu A. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. J Bone Joint Surg Am. 2008; 90:1265–71.
crossref
5. Bus MP, van de Sande MA, Fiocco M, Schaap GR, Bramer JA, Dijkstra PD. What are the long-term results of MUTARS® modular endoprostheses for reconstruction of tumor resection of the distal femur and proximal tibia? Clin Orthop Relat Res. 2017; 475:708–18.
6. Capanna R, Morris HG, Campanacci D, Del Ben M, Campa-nacci M. Modular uncemented prosthetic reconstruction after resection of tumours of the distal femur. J Bone Joint Surg Br. 1994; 76:178–86.
crossref
7. Guo W, Ji T, Yang R, Tang X, Yang Y. Endoprosthetic replacement for primary tumours around the knee: experience from Peking University. J Bone Joint Surg Br. 2008; 90:1084–9.
8. Zeegen EN, Aponte-Tinao LA, Hornicek FJ, Gebhardt MC, Mankin HJ. Survivorship analysis of 141 modular metallic endoprostheses at early followup. Clin Orthop Relat Res. 2004; 420:239–50.
crossref
9. Taylor SJ, Walker PS, Perry JS, Cannon SR, Woledge R. The forces in the distal femur and the knee during walking and other activities measured by telemetry. J Arthroplasty. 1998; 13:428–37.
crossref
10. Kawai A, Muschler GF, Lane JM, Otis JC, Healey JH. Prosthetic knee replacement after resection of a malignant tumor of the distal part of the femur. Medium to long-term results. J Bone Joint Surg Am. 1998; 80:636–47.
crossref
11. McDonald DJ, Capanna R, Gherlinzoni F. . Influence of chemotherapy on perioperative complications in limb salvage surgery for bone tumors. Cancer. 1990; 65:1509–16.
crossref
12. Berbari EF, Hanssen AD, Duffy MC. . Risk factors for prosthetic joint infection: case-control study. Clin Infect Dis. 1998; 27:1247–54.
crossref
13. Henderson ER, Groundland JS, Pala E. . Failure mode classification for tumor endoprostheses: retrospective review of five institutions and a literature review. J Bone Joint Surg Am. 2011; 93:418–29.
crossref
14. Kinkel S, Lehner B, Kleinhans JA, Jakubowitz E, Ewerbeck V, Heisel C. Medium to long-term results after reconstruction of bone defects at the knee with tumor endoprostheses. J Surg Oncol. 2010; 101:166–9.
crossref
15. Griffin AM, Parsons JA, Davis AM, Bell RS, Wunder JS. Uncemented tumor endoprostheses at the knee: root causes of failure. Clin Orthop Relat Res. 2005; 438:71–9.
16. Ahlmann ER, Menendez LR, Kermani C, Gotha H. Survivor-ship and clinical outcome of modular endoprosthetic reconstruction for neoplastic disease of the lower limb. J Bone Joint Surg Br. 2006; 88:790–5.
crossref

Figure 1
Preoperative radiograph of locking mechanism failure after distal femoral reconstruction (case 1). There is no definite signs of loosening around the femoral stem, but there is a radioopaque line (arrow) by the medial aspect of the femoral component, indicating breakage of the locking mechanism.
jkoa-52-435f1.tif
Figure 2
(A) Photograph of the retrieved locking mechanism (PEEK-OPTIMA) shows a breakage at the slot for knee motion, perpendicular to the long axis of the PEEK. (B) Radiography of the intact PEEK shows a radioopaque line on the right side.
jkoa-52-435f2.tif
Table 1
Demographic Data of the Whole Cohort
Variable Value
Patient 94
Gender (male/female) 52/42
Mean age (yr) 29 (11–86)
Diagnosis
Osteosarcoma
Conventional 77
Low grade 5
Benign aggressive 6
Other sarcoma 4
Metastatic 2

Values are presented as number only or median (range).

Table 2
Characteristics of Patients Experiencing Locking Mechanism Breakage
Patient No. Gender Age (yr) Height (cm) Body weight (kg) BMI (kg/m2) Bone resection (cm) Time interval to breakage (mo) F/U duration (mo)
1 Male 34 174 74 24.4 12 72 103
2 Male 21 181 85 25.9 16 66 89
3 Male 21 180 73 22.5 24 22/8 62
4 Female 54 159 64 25.3 10 26/6/16 63
5 Female 31 162 67 25.5 14 12/13/13/11 56
6 Male 15 180 89 24.5 24 16/14/4/11 55
7 Female 13 161 53 20.5 20 39 51
8 Female 48 151 56 24.6 14 33 40
9 Male 18 181 80 24.4 12 16/7/12 40
10 Female 35 167 83 29.4 18 27 39

BMI, body mass index; F/U, follow-up.

Table 3
Comparison of Clinical Variables Based on Locking Mechanism Breakage
Variable Patients without breakage (n=84) Patients with breakage (n=10) p-value
Gender (male/female) 47/37 5/5 0.748
Age (yr) 28.5±19.4 28.7±14.1 0.465
Height (cm) 163.5±8.6 168.5±11.1 0.097
Body weight (kg) 58.4±11.7 67.4±11.7 0.019
BMI (kg/m2) 21.7±3.3 23.5±2.1 0.053
Resected bone length (cm) 16.2±4.9 15.5±4.2 0.782
Tumor volume (ml) 198.1±27.4 207.1±47.8 0.378
Femoral stem diameter (cm) ) 14.5±1.8 14.2 ± 2.0 0.757

Values are presented as number only or mean±standard deviation. BMI, body mass index.

TOOLS
Similar articles